Major players in the tumor infiltrating lymphocytes market are Bellicum Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Precision BioScience Inc., Bluebird.
/PRNewswire/ Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it will.
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian's lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.